BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12775748)

  • 1. Why not start with thalidomide?
    Loprinzi C; Rajkumar SV
    J Clin Oncol; 2003 Jun; 21(11):2211-4. PubMed ID: 12775748
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalidomide in the treatment of multiple myeloma.
    Rajkumar SV
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):20-8. PubMed ID: 12113124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
    Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
    Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
    [No Abstract]   [Full Text] [Related]  

  • 4. [Thalidomide for the treatment of refractory multiple myeloma].
    Kakimoto T; Hattori Y; Okamoto S
    Rinsho Ketsueki; 2002 May; 43(5):345-8. PubMed ID: 12096483
    [No Abstract]   [Full Text] [Related]  

  • 5. [Thalidomide: (re)discovery of a not very dear old molecule].
    Bressoud A; Schwab BZ
    Rev Med Suisse Romande; 2003 Apr; 123(4):238-40. PubMed ID: 15088555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose of thalidomide in the treatment of refractory myeloma.
    Pini M; Baraldi A; Pietrasanta D; Allione B; Depaoli L; Salvi F; Levis A
    Haematologica; 2000 Oct; 85(10):1111-2. PubMed ID: 11025615
    [No Abstract]   [Full Text] [Related]  

  • 7. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach].
    Hattori Y; Kakimoto T
    Rinsho Ketsueki; 2000 May; 41(5):426-9. PubMed ID: 10879105
    [No Abstract]   [Full Text] [Related]  

  • 8. On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma.
    Ribatti D; Vacca A
    Ann Hematol; 2003 Apr; 82(4):262. PubMed ID: 12707735
    [No Abstract]   [Full Text] [Related]  

  • 9. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
    Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
    Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thalidomide: present and future in multiple myeloma.
    Hussein MA
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thalidomide--a treatment for cancer?
    Mayo Clin Health Lett; 2000 Jun; 18(6):4. PubMed ID: 10868128
    [No Abstract]   [Full Text] [Related]  

  • 12. Thalidomide.
    Waldman AR
    Clin J Oncol Nurs; 2000; 4(2):99-100. PubMed ID: 11107384
    [No Abstract]   [Full Text] [Related]  

  • 13. Thalidomide shows promise as cancer treatment.
    Health News; 2000 Jan; 6(1):8. PubMed ID: 11019665
    [No Abstract]   [Full Text] [Related]  

  • 14. [Thalidomide and others: new treatment for myeloma].
    Malphettes M; Fermand JP
    Rev Prat; 2003 Oct; 53(15):1633-5. PubMed ID: 14689905
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
    Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
    Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thalidomide--a revival story.
    Raje N; Anderson K
    N Engl J Med; 1999 Nov; 341(21):1606-9. PubMed ID: 10564693
    [No Abstract]   [Full Text] [Related]  

  • 17. Total therapy 2 in treatment of multiple myeloma: questions about gene expression profiling and treatment-related mortality.
    Mehta J
    J Clin Oncol; 2011 Feb; 29(5):e124; author reply e125-6. PubMed ID: 21172887
    [No Abstract]   [Full Text] [Related]  

  • 18. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.
    Oliveira AM; Maria DA; Metzger M; Linardi C; Giorgi RR; Moura F; Martinez GA; Bydlowski SP; Novak EM
    Leuk Res; 2009 Jul; 33(7):970-3. PubMed ID: 18976811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients.
    Corso A; Lorenzi A; Zappasodi P; Invernizzi R; Vanelli L; Lazzarino M
    Haematologica; 2003 Aug; 88(8):958-60. PubMed ID: 12935985
    [No Abstract]   [Full Text] [Related]  

  • 20. Thalidomide and thrombosis.
    Mehta P
    Clin Adv Hematol Oncol; 2003 Aug; 1(8):464-5. PubMed ID: 16258433
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.